Possible Role of 5-Alpha Reductase Inhibitors in Non-Invasive Bladder Urothelial Neoplasm: Multicentre Study

    December 2019 in “ Minerva Urology and Nephrology ”
    Antonio Luigi Pastore, Andrea Fuschi, Cosimo De Nunzio, Matteo Balzarro, Yazan Al Salhi, G. Velotti, Alessia Martoccia, Lorenzo Capone, Nelia Amigoni, Mario Falsaperla, Consalvo Mattia, Walter Artibani, Andrea Tubaro, Antonio Carbone
    Image of study
    TLDR 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
    The study evaluated the role of 5-alpha reductase inhibitors (5-ARIs) in non-muscle invasive bladder cancer (NMIBC) by retrospectively analyzing data from 423 patients. Patients treated with 5-ARIs had a significantly lower recurrence rate (14%) compared to untreated patients (37%), and a higher recurrence-free survival rate. The treated group also had fewer high-grade tumors and muscle invasive tumors. The findings suggested that long-term 5-ARI treatment might reduce bladder tumor recurrence and lesion extension, and improve recurrence-free survival. The study recommended a long-term, randomized prospective study to confirm these results.
    Discuss this study in the Community →